Navin Fluorine International Limited has reported a resilient performance for the fiscal year ending March 31, 2026. The company achieved six consecutive quarters of revenue and profit growth, driven by broad-based expansion across its Specialty Chemicals, CDMO, and HPP business verticals. With a 34% year-on-year revenue growth in Q4, the firm remains focused on commissioning key projects and maintaining a robust balance sheet to support long-term value creation.
Fiscal Year 2026 Financial Highlights
For the full financial year 2026, Navin Fluorine reported net operating revenues of INR 3,314 crores, marking a 41% growth. The company’s operating EBITDA more than doubled to INR 1,082 crores, with margins expanding to 32.6%. Profit after tax saw a significant rise to INR 664 crores, compared to INR 289 crores in the previous year. Reflecting this robust performance, the Board declared a final dividend of INR 8.6 per equity share, representing 430% of the face value.
Segmental Performance Breakdown
The company experienced strong growth across all three major business verticals:
- High-Performance Products (HPP): Q4 revenue grew by 20% year-on-year to INR 393 crores, bolstered by the commissioning of the AHF plant and upcoming R32 capacity expansion.
- Specialty Chemicals: Revenue for Q4 reached INR 360 crores, a 39% increase, supported by the successful execution of both existing and new molecules.
- CDMO Business: This segment reported a 61% year-on-year growth in Q4 to INR 186 crores, driven by a balanced mix of early-stage, late-stage, and commercial molecules across various therapeutic areas.
Strategic Outlook and Expansion
Navin Fluorine is transitioning several key projects from the investment phase to revenue generation in the new financial year. The company is particularly focused on its Chemours project, which is on track for commissioning by June or July 2026, and the ramp-up of additional HFC capacities. Management emphasized that despite geopolitical uncertainties, the company remains resilient, with a strong order book and clear visibility into FY27 growth, supported by a healthy balance sheet and improved net working capital cycles.
Source: BSE
